A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Definitive Phase III Study of the Effects of Ferric Citrate on Serum Phosphate in Subjects With End Stage Renal Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Kaohsiung, Taiwan
- Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang-Gung Memorial Hospital
-
Keelung, Taiwan
- Division of Nephrology, Keelung Chang Gung Memorial Hospital
-
New Taipei City, Taiwan
- Division of Nephrology, Department of Internal Medicine, Far East Memorial Hospital
-
Taichung, Taiwan
- Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital
-
Taipei, Taiwan
- Division of Nephrology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age>18 years and has a diagnosis of ESRD
- On a three-times per week hemodialysis regimen
- On a stable dose of a phosphate-binding agent for at least one month prior to study entry.
- If on vitamin D supplementation or calcitriol, must be on a stable dose for at least one month prior to study entry.
- Hct >= 20%
- Serum Ca level of 8 mg/dL to 10.5 mg/dL
Exclusion Criteria:
- Is pregnant or lactating
- Clinically significant GI disorder
- Has tertiary hyperparathyroidism or is immediately post-operative from a parathyroidectomy (within the first 3 months post-op or the plasma Ca is <7 mg/dL)
- ferritin>800 ng/mL
- Unstable medical condition unsuitable for the study in the opinion of investigator
- Has been treated with an investigational agent within 30 days of enrollment
- Has a history of documented iron allergy or hemochromatosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
0g/day ferric citrate capsule, TID for 56 days
4g/day ferric citrate capsule, TID for 56 days
6 g/day ferric citrate capsule, TID for 56 days
|
|
Experimental: 4g/day
Ferric Citrate for a total daily dose of 4g
|
0g/day ferric citrate capsule, TID for 56 days
4g/day ferric citrate capsule, TID for 56 days
6 g/day ferric citrate capsule, TID for 56 days
|
|
Experimental: 6g/day
Ferric Citrate for a total daily dose of 6g
|
0g/day ferric citrate capsule, TID for 56 days
4g/day ferric citrate capsule, TID for 56 days
6 g/day ferric citrate capsule, TID for 56 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in serum phosphorus at Day 56 as compared to baseline
Time Frame: Day 56
|
Day 56
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in serum phosphorus at Day 28 as compared to baseline
Time Frame: Day 28
|
Day 28
|
|
Change in Ca x P product at Day 56 compared to baseline
Time Frame: Day 56
|
Day 56
|
|
Change in Ca x P product at Day 28 compared to baseline
Time Frame: Day 28
|
Day 28
|
|
Cumulative drop out rate due to serum phosphorus concentration >9mg/dL at Day 56
Time Frame: Day 56
|
Day 56
|
|
Cumulative drop out rate due to serum Phosphorus concentration >9mg/dL at Day 28
Time Frame: Day 28
|
Day 28
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Urologic Diseases
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Phosphorus Metabolism Disorders
- Kidney Diseases
- Kidney Failure, Chronic
- Hyperphosphatemia
- Molecular Mechanisms of Pharmacological Action
- Anticoagulants
- Hematinics
- Chelating Agents
- Sequestering Agents
- Calcium Chelating Agents
- Citric Acid
- Sodium Citrate
- Ferric Compounds
Other Study ID Numbers
Other Study ID Numbers
- PNC00301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.